/ Natco Launches Velpanat In Nepal Stocks Up ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 2 January 2017

Natco Pharma Limited announced today that it has launched the first generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination in Nepal. Natco Pharma Ltd is currently trading at Rs 585, up by Rs 4.4 or 0.76% from its previous closing of Rs 580.6 on the BSE.

Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination is sold by Gilead Sciences, Inc., under brand name Epclusa - the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin.

Natco will market Sofosbuvir 400mg/Velpatasvir 100mg under the brand name Velpanat. Natco priced its generic medicine of Velpanat at Rs 25,000 equivalent for a bottle of 28 tablets in Nepal. Natco has signed a non-exclusive licensing agreement with Gilead Sciences, Inc., to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries.

The scrip opened at Rs 600 and has touched a high and low of Rs 600 and Rs 582.5 respectively. So far 94080(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 10120.31 crore. The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 703.95 on 25-Aug-2016 and a 52 week low of Rs 390 on 29-Mar-2016. Last one week high and low of the scrip stood at Rs 610 and Rs 555.5 respectively.

The promoters holding in the company stood at 51.28 % while Institutions and Non-Institutions held 25.89 % and 22.83 % respectively.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717